Hagens Berman is investigating claims in a securities class action against Erasca, Inc. alleging the company misled investors about its lead oncology candidate ERAS-0015. The investigation follows disclosures on April 27 and 28, 2026, that triggered a sharp stock decline and wiped out over $2.8 billion in market capitalization. The litigation claims Erasca used flawed preclinical comparisons to assert superiority over competing therapies, concealed intellectual property disputes with Revolution Medicines, and downplayed safety risks that later surfaced after a patient death in the ERAS-0015 trial. Investors who purchased Erasca common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek appointment as lead plaintiff.
Erasca IncSecurities fraud investigation and class action alleging misleading disclosures and safety risks.
Revolution Medicines Inc